Use of protein biomolecular targets in the treatment and...

Details Use of protein biomolecular targets in the treatment and... Use of protein biomolecular targets in the treatment and...

2006-06-13

2006-06-13

Siew, Jeff (Department: 1642)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

C436S023000, C436S023000, C436S023000

Reexamination Certificate

active

07060275

ABSTRACT:
The present invention relates to the use of proteins which are differentially expressed in primary brain tumor tissues, as compared to normal brain tissues, as biomolecular targets for brain tumor treatment therapies. Specifically, the present invention relates to the use of immunotherapeutic and immunoimaging agents which specifically bind to one or more of human proteins angiopoietin related protein 2 (ARP-2,) secreted protein acidic, rich in cysteine (SPARC,) c-met proto-oncogene (C-MET,) brevican (BEHAB,) CD-44 antigen (CD-44,) tetraspanin 3 (TSPN3,) pleiotrophin (PTN,) osteopontin (OPN,) vasoactive intestinal peptide receptor-2 (VIPR-2,) and receptor protein tyrosine phosphatase zeta (PTPζ) for the treatment and visualization of brain tumors in patients. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the methods of the invention. The present invention also provides novel splice variants of protein PTPζ, PTPζ SM1 and PTPζ SM2. Nucleic acid probes specific for the spliced mRNA encoding these variants and affinity reagents specific for the novel proteins are also provided.

REFERENCES:
patent: 4565789 (1986-01-01), Liotta et al.
patent: 4861710 (1989-08-01), Sobel et al.
patent: 5648273 (1997-07-01), Bottaro et al.
patent: 5686292 (1997-11-01), Schwall et al.
patent: 5720720 (1998-02-01), Laske et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5871959 (1999-02-01), Rong et al.
patent: 5945098 (1999-08-01), Sarno et al.
patent: 6020179 (2000-02-01), Goli
patent: 6034218 (2000-03-01), Reed et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6063905 (2000-05-01), Capra et al.
patent: 6147203 (2000-11-01), Pastan et al.
patent: 6174708 (2001-01-01), Sodoyer et al.
patent: 6187287 (2001-02-01), Leung et al.
patent: 6312686 (2001-11-01), Staddon et al.
patent: 6455026 (2002-09-01), Mueller et al.
patent: 0 520 158 (1992-12-01), None
patent: 0 890 361 (1999-01-01), None
patent: 0 962 530 (1999-12-01), None
patent: 1 074 264 (2001-02-01), None
patent: WO 93/15754 (1993-08-01), None
patent: WO 98/19696 (1998-05-01), None
patent: WO 98/29138 (1998-07-01), None
patent: WO 98/53838 (1998-12-01), None
patent: WO 00/10506 (2000-03-01), None
patent: WO 00/20869 (2000-04-01), None
patent: WO 00/40264 (2000-07-01), None
patent: WO 00/59938 (2000-10-01), None
patent: WO 00/70076 (2000-11-01), None
patent: WO 00/72679 (2000-12-01), None
patent: WO 00/78361 (2000-12-01), None
patent: WO 01/09159 (2001-02-01), None
patent: WO 01/13105 (2001-02-01), None
Krueger et al. (Proc. Natl. Acad. Sci. USA 1992; 89: 7417-7421).
Streuli et al. (Proc. Natl. Acad. Sci. 1989; 86: 8698-8702).
Abounader, R. et al., “Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human flioblastoma”,Journal of Neurochemistry, vol. 76, pp. 1497-1508, 2001.
Asher, R. et al., “Hyaluronate Binding and CD44 Expression in Human Glioblastoma Cells and Astrocytes”,Experimental Cell Research, vol. 203, pp. 80-90, 1992.
Aspberg, A. et al., “The C-type lectin domains of lecticans, a family of aggregating chondroitin sulfate proteoglycans, bind tenascin-R by protein-protein interactions independent of carbohydrate moiety”,Proc. Natl. Acad. Sci. USA, vol. 94, pp. 1016-10121, Sep. 1997.
Bajorath, J., “Molecular Organization, Structural Features, and Ligand Binding Characteristics of CD44, a Highly Variable Cell Surface Glycoprotein With Multiple Functions”,Proteins: Structure, Function, and Genetics, vol. 39, No. 2, May 2000.
Bartus, R.T., et al., “Evidence that Cereport's Ability to Increase Permeability of Rat Gliomas is Dependent Upon Extent of Tumor Growth: Implications for Treating Newly Emerging Tumor Colonies”,Experimental Neurology, vol. 161, No. 1, pp. 234-244, Jan. 2000.
Berditchevski, F. et al., “Characterization of integrin- Tetraspanin Adhesion Complexes: role of Tetraspanins in Integrin Signaling”,J. Cell Biology, vol. 146, No. 2, pp. 477-492, Jul. 1999.
Bickel, U. et al., “Delivery of peptides and proteins through the blood-brain barrier”,Advanced Drug Delivery Reviews, vol. 46, pp. 247-279, 2001.
Birling, M. et al., “A Novel Rat Tetraspan Protein in Cells of the Oligodendrocyte Lineage”,J. Neurochem., vol. 73, pp. 2600-2608, 1999.
Castronovo, V., “Laminin Receptors and Laminin-Binding Proteins during Tumor Invasion and Metastasis”,Invasion Metastasis, vol. 13, pp. 1-30, 1993.
Castronovo, V., et al., “Laminin and fibronectin increase the steady state level of the 67 kD high affinity metastasis- associated laminin receptor mRNA in human cancer cells”,Biochemical and Biophysical Research Communications, vol. 168, No. 3, pp. 1110-1117, May 16, 1990
Cawthern, K.M. et al., “Blood Coagulation in Hemophilia A and Hemophilia C”,Blood, vol. 91, No. 12, pp. 4581-4592, 1998.
Charrin, S. et al., “The major CD9 and CD81 molecular partner: Identification and characterization of the complexes”,The American Society for Biochemistry and Molecular Biology, Inc., JEC Papers in Press, Published on Jan. 18, 2001 as Manuscript MO11297200.
Crepaldi, T. et al., “Generation of a Truncated Hepatocyte Growth Factor Receptor in the Endoplasmic Reticulum”,J. Biol. Chem., vol. 269, No. 3, pp. 1750-1755, 1994.
Czubayko, F., et al., “Ribozyme-targeting Elucidates a Direct Role of Pleiotrophin in Tumor Growth”,J. Biol. Chem., vol. 269, No. 33, pp. 21358-21363, Aug. 15, 1994.
Dean, M. et al., “Characterization of the Rearranged tpr-met Oncogene Breakpoint”,Molecular and Cellular Biology, vol. 7, No. 2, pp. 921-924, 1987.
Domanico, S.Z. et al., “Integrin α6Aβ1 Induces CD81-dependent Cell Motility without Engaging the Extracellular Matrix Migration Substrate”,Molecular Biology of the Cell, vol. 8. pp. 2253-2265, Nov. 1997.
Engering, A. et al., “Association of distinct tetraspanins with MHC class II molecules at different subcellular locations in human immature dendritic cells”,International Immunology, vol. 13, No. 2, pp. 127-134 2001.
Fang, W. et al., “Pleiotrophin Stimulátes Fibroblasts and Endothelial and Epithelial Cells and Is Expressed in Human Cancer”,J. Biol. Chem., vol. 267, No. 36, pp. 25889-25897, 1992.
Ferrer, M. et al., “Pattern of expression of tetraspanin antigen genes in Burkitt lymphoma cell lines”,Clin. Exp. Immunol., vol. 113, pp. 346-352, 1998.
Fischer, U. et al., “Amplification of the MET Gene in Glioma”,Genes, Chromosomes& Cancer, vol. 12, No. 1, pp. 63-65 (1995).
Föger, N. et al., “CD44 supports T cell proliferation and apoptosis by apposition of protein kinases”,Eur. J. immunol., vol. 30, No. 10, pp. 2888-2899, 2000.
Galimi, F. et al., “The Hepatocyte Growth Factor and Its Receptor”,Stem Cells, vol. 11 (Suppl. 2), pp. 22-30, 1993.
Gary S.C., et al., “BEHAB/brevican: An Extracellular Matrix Component-Associated with Invasive Glioma”,ClinicalNeurosurgery, vol. 47, pp. 72-82, 1999.
Gary, S.C. et al., “BEHAB/Brevican: a brain-specific lectican implicated in gliomas and glial cell motility”,Current Opinion in Neurobiology, vol. 8, pp. 576-581, 1998.
Gary, S.C. et al., “cDNA cloning, chromosomal localization, and expression analysis of human BEHAB/brevican, a brain specific proteoglycan regulated during cortical development and in glioma”,Gene, vol. 256, pp. 139-147, 2000.
Gladson, C.L., “The Extracellular Matrix of Gliomas: Modulation of Cell Function”,Journal of Neuropathology and Experimental Neurology, vol. 58, No. 10, pp. 1029-1040, Oct., 1999.
Golembieski, W.A. et al., “Increased SPARC Expression Promotes U87 Glioblastoma invation In Vitro”,Int. J. Devl. Neuroscience, vol. 17, Nos. 5, 6, pp. 463-472, 1999.
Harabin-Slowinska, M. et al., “Expression of Adhesion

Affiliated with

Also associated with

Rating

Use of protein biomolecular targets in the treatment and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of protein biomolecular targets in the treatment and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of protein biomolecular targets in the treatment and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3626143